Store at -20C

VEGF-B Antibody



877-616-CELL (2355)

orders@cellsignal.com

877-678-TECH (8324) Support:

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

Applications: WB	Reactivity: H	Sensitivity: Recombinant protein	MW (kDa): 20	Source: Rabbit	UniProt ID: #P49765	Entrez-Gene Id 7423
Product Usage Information	Application			Dilution		
	We	Western Blotting			1:1000	
Storage		plied in 10 mM sodi C. Do not aliquot the	· ·	i), 150 mM NaCl, 10	00 μg/ml BSA and 50% ç	glycerol. Store at –
		VEGF-B Antibody detects recombinant human VEGF-B protein at various concentrations. This antibody does not cross-react with other VEGF family members.				
Source / Purifica	resi	Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly112 of human VEGF-B. Antibodies are purified by protein A and peptide affinity chromatography.				

Background Vascular endothelial growth factor (VEGF) is a highly specific mitogen for vascular endothelial cells. VEGF

and its close relatives VEGF-B, -C and -D form a subfamily within PDGF family of growth factors, which belongs to the cysteine knot class of cytokines. Five VEGF isoforms of 121, 145, 165, 189 and 206 amino acids (VEGF121-206) are generated as a result of alternative splicing from a single VEGF gene (1). The various VEGF forms bind to three tyrosine-kinase receptors, VEGFR-1, VEGFR-2 and VEGFR-3 which are expressed almost exclusively in endothelial cells. VEGFR-2 is the main angiogenic signal transducer for VEGF, while VEGFR-3 is specific for VEGF-C and -D and is necessary and sufficient for lymphangiogenic signaling. However, upon proteolytic processing VEGF-C and -D gain the ability to also bind and activate VEGFR-2 (2). Guided by the binding properties of the ligands, the VEGFRs are able to form both homodimers and heterodimers. Receptor dimerization is accompanied by activation of receptor kinase activity leading to receptor autophosphorylation. Phosphorylated receptors recruit interacting proteins and induce downstream signaling (3). Recently, tumor therapies based on neutralizing anti-VEGF antibodies and small molecule tyrosine kinase inhibitors targeting VEGFRs have been developed. These new strategies for tumor treatment show the clinical relevance of inhibiting VEGF signal transduction pathways that are exaggerated in pathological angiogenesis (4).

Background References

- 1. Olsson, A.K. et al. (2006) Nat. Rev. Mol. Cell Biol. 7, 359-371.
- 2. Gluzman-Poltorak, Z. et al. (2001) J. Biol. Chem. 276, 18688-18694.
- 3. Matsumoto, T. and Mugishima, H. (2006) J. Atheroscler. Thromb. 13, 130-135.
- 4. Gatto, B. and Cavalli, M. (2006) Anticancer Agents Med. Chem. 6, 287-301.

Species Reactivity Species reactivity is determined by testing in at least one approved application (e.g., western blot).

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, **Western Blot Buffer**

0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key WB: Western Blotting

Cross-Reactivity Key H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster

X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse

GP: Guinea Pig Rab: rabbit All: all species expected

Trademarks and

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. **Patents**

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more

information.

Limited Uses

VEGF-B Antibody (#2463) Datasheet Without Images Cell Signaling Technology

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.